Up until now Recce has held up surprisingly well compared to other biotechs. There has been carnage across the whole sector. Smells a bit like EOFY tax selling. Only takes a few holders to liquidate to drop the price with the fairly minuscule volumes. Here’s hoping combination of continued progress on sepsis trials and a new financial year. This cohort finishes on the 17 June ie next week so should get read out week following…. no dates on next cohort yet which is interesting. They have had them scheduled out a month in advance, to date. Be nice to get an announcement on what is planned for next stage of sepsis trials, assumedly treating actual sepsis patients. Surely their focus now much be very much on that and here’s hoping there is not a big air gap till we launch those.
RCE Price at posting:
61.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)